Sponsored by MilliporeSigma
As a combined result of increases in research and medical diagnostic immunoassay volumes, pressure on the global supply system of animal hosts and other traditional means of antibody production has grown tremendously. Specifically, the shortage of animal-derived materials because of the COVID-19 pandemic has spiked their demand, highlighting the need for sustainable and robust means of producing critical reagents. Our Antibody manufacturing capabilities enable us to provide complete support for custom antibody generation and large-scale manufacturing. Our goal is to ensure the highest quality products by using our custom antibody generation platform and incorporating recombinant antibody technology and antibody engineering. The antibody manufacturing platform includes antigen design, immunization development program, B-cell cloning, clone generation and selection, recombinant expression, and stable cell line generation. The manufacturing capabilities enable our team to produce large-scale batches while providing lot consistency, high quality antibodies and a secure supply.
Privacy Policy